Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q3 FY21 results · Oct–Dec 2020
Torrent Pharmaceuticals reported revenue from operations of ₹1,995.00 crore (up 1.5% from Q3 FY20) and net profit of ₹297.00 crore (up 18.3% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,995.00 | 1,966.00 | +1.5% | 2,017.00 | −1.1% |
| Other income | 8.00 | 53.00 | −84.9% | 6.00 | +33.3% |
| Total income | 2,003.00 | 2,019.00 | −0.8% | 2,023.00 | −1.0% |
| Profit before tax | 357.00 | 319.00 | +11.9% | 384.00 | −7.0% |
| Net profit for the period | 297.00 | 251.00 | +18.3% | 310.00 | −4.2% |
| EPS, basic (₹) | 17.52 | 14.77 | +18.6% | 18.32 | −4.4% |
| Net margin (%) | 14.9 | 12.8 | 15.4 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,616.00 | 1,471.00 | +9.9% | 1,640.00 | −1.5% |
| Other income | 11.00 | 62.00 | −82.3% | 9.00 | +22.2% |
| Total income | 1,627.00 | 1,533.00 | +6.1% | 1,649.00 | −1.3% |
| Profit before tax | 339.00 | 252.00 | +34.5% | 356.00 | −4.8% |
| Net profit for the period | 278.00 | 220.00 | +26.4% | 283.00 | −1.8% |
| EPS, basic (₹) | 16.45 | 12.97 | +26.8% | 16.68 | −1.4% |
| Net margin (%) | 17.2 | 15.0 | 17.3 |
Consolidated
- Filed with BSE
- 08 Feb 2021, 18:49 IST
- Board meeting
- 08 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Feb 2021, 18:49 IST
- Board meeting
- 08 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Audited
- Source
- XBRL filing on BSE